Tamar Polonsky, MD, MSCI, is a general cardiologist who treats a wide range of cardiac conditions, including coronary artery disease, hypertension, hyperlipidemia (high cholesterol) and valve disease.
Dr. Polonsky also specializes in the management of heart disease in cancer patients (cardio-oncology). She works closely with oncologists and surgeons to take care of patients with preexisting heart disease and to help monitor for potential cardiac complications from chemotherapy and radiation.
Dr. Polonsky has research expertise in cardiovascular epidemiology and prevention. She has experience analyzing data from large cohort studies, with the aim of finding novel ways to predict a person's risk of developing heart disease.
Nocturnal Oxygen Therapy for Central Sleep Apnea in Patients with Heart Failure: A Multisite, Double-Blind, Sham-controlled Randomized Clinical Trial (LOFT-HF).
Nocturnal Oxygen Therapy for Central Sleep Apnea in Patients with Heart Failure: A Multisite, Double-Blind, Sham-controlled Randomized Clinical Trial (LOFT-HF). Ann Am Thorac Soc. 2025 Dec; 22(12):1951-1960.
PMID: 40929650
Transfusion Strategy Effect on Quality of Life in Patients With Myocardial Infarction and Anemia: A Secondary Analysis of the MINT Randomized Clinical Trial.
Transfusion Strategy Effect on Quality of Life in Patients With Myocardial Infarction and Anemia: A Secondary Analysis of the MINT Randomized Clinical Trial. JAMA Intern Med. 2025 Aug 01; 185(8):947-954.
PMID: 40459491
Association of study visit interval length with follow-up completeness and adherence to assigned study drug dose: A randomized comparison of participants in the ADAPTABLE trial.
Association of study visit interval length with follow-up completeness and adherence to assigned study drug dose: A randomized comparison of participants in the ADAPTABLE trial. Contemp Clin Trials. 2025 Sep; 156:108030.
PMID: 40716702
Individualized transfusion decisions to minimize adverse cardiovascular outcomes in patients with acute myocardial infarction and anemia.
Individualized transfusion decisions to minimize adverse cardiovascular outcomes in patients with acute myocardial infarction and anemia. Am Heart J. 2025 Apr; 282:146-155.
PMID: 39826701
Hepatocyte growth factor for walking performance in peripheral artery disease.
Hepatocyte growth factor for walking performance in peripheral artery disease. J Vasc Surg. 2025 Jun; 81(6):1467-1478.e1.
PMID: 39778757
The ankle-brachial index, gastrocnemius mitochondrial respirometry, and walking performance in people with and without peripheral artery disease.
The ankle-brachial index, gastrocnemius mitochondrial respirometry, and walking performance in people with and without peripheral artery disease. Vasc Med. 2024 12; 29(6):640-652.
PMID: 39239859
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA Cardiol. 2024 Sep 01; 9(9):808-816.
PMID: 38985488
Differing associations of PM2.5 exposure with systolic and diastolic blood pressures across exposure durations in a predominantly non-Hispanic Black cohort.
Differing associations of PM2.5 exposure with systolic and diastolic blood pressures across exposure durations in a predominantly non-Hispanic Black cohort. Sci Rep. 2024 08 31; 14(1):20256.
PMID: 39217205
Restrictive Versus Liberal Transfusion in Patients With Type 1 or Type 2 Myocardial Infarction: A Prespecified Analysis of the MINT Trial.
Restrictive Versus Liberal Transfusion in Patients With Type 1 or Type 2 Myocardial Infarction: A Prespecified Analysis of the MINT Trial. Circulation. 2024 Dec 03; 150(23):1826-1836.
PMID: 39206549
Management of Patients With Chronic Coronary Disease.
Management of Patients With Chronic Coronary Disease. JAMA. 2024 08 20; 332(7):585-586.
PMID: 39046710